New drugs for the treatment of tuberculosis: hope and reality [State of the Art Series. New tools. Number 2 in the series]

The objective of this review is to report evidence about the efficacy and potential of currently licensed drugs and new molecules beyond pre-clinical development for improving the chemotherapy of tuberculosis (TB). Rifapentine, a rifamycin with low minimum inhibitory concentration, long half-life an...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The international journal of tuberculosis and lung disease 2012-08, Vol.16 (8), p.1005-1014
Hauptverfasser:	Grosset, J. H., Singer, T. G., Bishai, W. R.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antibacterial agents Antibiotics. Antiinfectious agents. Antiparasitic agents Antitubercular Agents - chemistry Antitubercular Agents - pharmacology Antitubercular Agents - therapeutic use Bacterial diseases Biological and medical sciences Btz043 Clofazimine Drug Design Drug Resistance, Multiple, Bacterial Drug Therapy, Combination Drugs, Investigational - chemistry Drugs, Investigational - pharmacology Drugs, Investigational - therapeutic use Human bacterial diseases Humans Infectious diseases Medical sciences Moxifloxacin Mycobacterium Pa-824 And Opc-67683 Pharmacology. Drug treatments Pneumology Pnu-100480 And Azd-5847 rifapentine Sq109 Tmc207 Tuberculosis - diagnosis Tuberculosis - drug therapy Tuberculosis - microbiology Tuberculosis and atypical mycobacterial infections Tuberculosis, Multidrug-Resistant - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!